2017 Conference on Retroviruses and Opportunistic Infections

References

  1. Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237-2246.
  2. Montano MA, Dombrowski JC, Barbee LA, et al. Changes in sexual behavior and STI diagnoses among MSM using PrEP in Seattle, WA. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 979.
  3. Molina JM, Charreau I, Spire B, et al. Efficacy of on demand PrEP with TDF-FTC in the ANRS IPERGAY open-label extension study. Program and abstracts of the 21st International AIDS Conference; July 18-22, 2016; Durban, South Africa. Abstract WEAC0102.
  4. Molina JM, Charreau I, Chidiac C, et al. On demand post-exposure prophylaxis with doxycycline for MSM enrolled in a PrEP trial. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 91LB.
  5. Hoornenborg E, de Bree GJ. Acute infection with a wild-type HIV-1 virus in PrEP user with high TDF levels. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 953.
  6. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606-2615.
  7. Arribas JR, Thompson M, Sax PE, et al. Significant efficacy and long-term safety difference with TAF-based STR in naive adults. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 453.
  8. Wohl D, Oka S, Clumeck N, et al. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016;72:58-64.
  9. Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016;3:e410-e420.
  10. Hodder S, Squires K, Kityo C, et al. Efficacy and safety of switching to EVG/COBI/FTC/TAF in virologically suppressed women. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 443.
  11. Orrell C, Hagins D, Belonosova E, et al. Superior efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) compared with ritonavir (RTV) boosted atazanavir (ATV) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive women with HIV-1 infection (ARIA Study). Program and abstracts of the 21st International AIDS Conference; July 18-22, 2016; Durban, South Africa. Abstract THAB0205LB.
  12. Hernandez AL, Ocfemia MCB, Saduvala N, et al. HIV integrase genotypic testing and resistance in the United States—9 jurisdictions. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 478.
  13. Davy T, Brunet L, Napravnik S, et al. Low prevalence of HIV drug resistance with modern agents. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 483.
  14. Koullias Y, Sax PE, Walensky RP, et al. Should we be testing for baseline integrase resistance? Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 493.
  15. Hatano H, Lampiris H, Fransen S, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2010;54:389-393.
  16. Llibre JM, Hung CC, Brinson C, et al. Phase III SWORD 1&2: switch to DTG+RPV maintains virologic suppression through 48 weeks. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 44LB.
  17. Fulcher JA, Du Y, Sun R, et al. Emergence of integrase resistance mutations during initial therapy with TDF/FTC/DTG. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 500LB.
  18. ClinicalTrials.gov. A phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed (SWORD-1). Available at: https://clinicaltrials.gov/ct2/show/NCT02429791. Accessed April 17, 2017.
  19. ClinicalTrials.gov. A phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-, NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed (SWORD-2). Available at: https://clinicaltrials.gov/ct2/show/NCT02422797. Accessed April 17, 2017.
  20. Rilpivirine [package insert]. Titusville, NJ: Janssen Therapeutics; 2015.
  21. Joly V, Burdet C, Landman R, et al. Promising results of dolutegravir + lamivudine maintenance in ANRS 167 LAMIDOL trial. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 458.
  22. ClinicalTrials.gov. A phase III, randomised, double blind, multicentre, parallel group, non inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in human immunodeficiency virus 1 infected treatment naïve adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02831673. Accessed April 17, 2017.
  23. ClinicalTrials.gov. A phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02831764. Accessed April 17, 2017.
  24. ClinicalTrials.gov. Dolutegravir antiretroviral strategy to promote improvement and reduce drug exposure (ASPIRE) study. Available at: https://clinicaltrials.gov/ct2/show/NCT02263326. Accessed April 17, 2017.
  25. Girouard MP, Sax PE, Parker RA, et al. The cost-effectiveness and budget impact of 2-drug dolutegravir-lamivudine regimens for the treatment of HIV infection in the United States. Clin Infect Dis. 2016;62:784-791.
  26. Cahn P, Rolón MJ, Figueroa MI, et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: 48 week results of the PADDLE trial. Program and abstracts of the 21st International AIDS Conference; July 18-22, 2016; Durban, South Africa. Abstract FRAB0104LB.
  27. Oldenbuettel C, Wolf E, Ritter A, et al. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results. Antivir Ther. 2016;[Epub ahead of print].
  28. Gubavu C, Prazuck T, Niang M, et al. Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients. J Antimicrob Chemother. 2016;71:1046-1050.
  29. Katlama C, Soulié C, Caby F, et al. Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia. J Antimicrob Chemother. 2016;71:2646-2650.
  30. Rojas J, Blanco JL, Marcos MA, et al. Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression. J Antimicrob Chemother. 2016;71:1975-1981.
  31. Wijting I, Roks C, Boucher C, et al. Switching from cART to dolutegravir (DTG) maintenance monotherapy in virologically suppressed HIV-1 infected adults: a randomized multicenter, non-inferiority clinical trial (DOMONO). Program and abstracts of the 2016 International Congress of Drug Therapy in HIV Infection; October 23-26, 2016; Glasgow, United Kingdom. Abstract O333.
  32. Wijting I, Rokx C, Boucher C, et al. Dolutegravir as maintenance monotherapy for HIV-1: a randomized clinical trial. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 451LB.
  33. Blanco JL, Oldenbuettel C, Thomas R, et al. Pathways of resistance in subjects failing dolutegravir monotherapy. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 42.
  34. Feng M, Sachs NA, Xu M, et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016;60:2241-2247.
  35. Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20:397-405.
  36. Molina JM, Squires K, Sax PE, et al. Doravirine is non-inferior to darunavir + ritonavir in phase 3 treatment-naive trial at week 48. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 45LB.
  37. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. Available at: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 17, 2017.
  38. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV Infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 2016;316:191-210.
  39. Reust CE. Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician. 2011;83:1443-1451.
  40. Ryom L, Lundgren JD, El-Sadr WM, et al. Association between cardiovascular disease & contemporarily used protease inhibitors. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 128LB.
  41. Jones G, Goldsmith J, Mulato A, et al. GS-9883, a novel HIV-1 integrase strand transfer inhibitor (INSTI) with optimized in vitro resistance profile. Program and abstracts of the American Society for Microbiology Microbe 2016 annual meeting; June 16-20, 2016; Boston, Massachusetts. Abstract 413.
  42. Lazerwith S, Cai R, Chen X, et al. Discovery of GS-9883, an HIV-1 integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and in vitro resistance profile. Program and abstracts of the American Society for Microbiology Microbe 2016 annual meeting; June 16-20, 2016; Boston, Massachusetts. Abstract 414.
  43. Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60:7086-7097.
  44. White K, Cihlar T, Miller MD. Potent activity of GS-9883, a novel unboosted HIV-1 integrase strand transfer inhibitor (INSTI), against patient isolates with INSTI-resistance. Program and abstracts of the 14th European Meeting on HIV & Hepatitis 2016; May 25-27, 2016; Rome, Italy. Abstract O_1.
  45. White K, Majka A, Novikov N, et al. The integrase strand transfer inhibitor bictegravir has a long integrase/DNA dissociation half-life. Program and abstracts of the 2016 International Congress of Drug Therapy in HIV Infection; October 23-26, 2016; Glasgow, United Kingdom. Abstract P025.
  46. White KL, Niedziela-Majka A, Novikov N, et al. Bictegravir dissociation half-life from HIV-1 G140S+Q148H integrase/DNA complexes. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 497.
  47. Gallant J, Thompson M, Mills T, et al. Novel INSTI GS-9883 10 day monotherapy in HIV-1 infected subjects. Programs and abstracts of the American Society for Microbiology Microbe 2016 annual meeting; June 16-20, 2016; Boston, Massachusetts. Abstract PW-030.
  48. Sax PE, DeJesus E, Crofoot G, et al. Randomized trial of bictegravir or dolutegravir with FTC/TAF for initial HIV therapy. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 41.
  49. Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;[Epub ahead of print].
  50. Zhang H, Custodio JM, Wei X, et al. Clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 40.
  51. Hoffmann C, Welz T, Sabranski M, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56-63.
  52. ClinicalTrials.gov. Safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus abacavir/dolutegravir/lamivudine in HIV-1 infected, antiretroviral treatment-naive adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02607930. Accessed April 17, 2017.
  53. ClinicalTrials.gov. Safety and efficacy of bictegravir/emtricitabine/tenofovir alafenamide versus dolutegravir + emtricitabine/tenofovir alafenamide in HIV-1 infected, antiretroviral treatment-naive adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02607956. Accessed April 17, 2017.
  54. ClinicalTrials.gov. Safety and efficacy of switching from regimens consisting of boosted atazanavir or darunavir plus either emtricitabine/tenofovir or abacavir/lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV-1 infected adults. Available at: https://clinicaltrials.gov/ct2/show/NCT02603107. Accessed April 17, 2017.
  55. ClinicalTrials.gov. Safety and efficacy of switching from dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 infected adults who are virologically suppressed. Available at: https://clinicaltrials.gov/ct2/show/NCT02603120. Accessed April 17, 2017.
  56. Bruno CJ, Jacobson JM. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J Antimicrob Chemother. 2010;65:1839-1841.
  57. Lewis S, et al. Long-acting ibalizumab in patients with multi-drug resistant HIV-1: a 24-week study. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 449LB.
  58. Hansel TT, Kropshofer H, Singer T, et al. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325-338.
  59. Thompson M, Lalezari JP, Kaplan R, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a phase IIb, randomized controlled trial. Antivir Ther. 2016;[Epub ahead of print].
  60. Margolis DA, Brinson C, Smith G, et al. Long-term safety and efficacy of CAB and RPV as 2-drug oral maintenance therapy. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 442.
  61. Margolis D, Podzamczer D, Stellbrink HJ, et al. Cabotegravir + rilpivirine as long-acting maintenance therapy: LATTE2 week 48 results. Program and abstracts of the 21st International AIDS Conference; July 18-22, 2016; Durban, South Africa. Abstract THAB0206LB.
  62. Margolis DA, Brinson CC, Smith GH, et al. Cabotegravir and rilpivirine as 2-drug oral maintenance therapy: LATTE W96 results. Program and abstracts of the 2015 Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, Washington. Abstract 554LB.
  63. Margolis DA, Brinson CC, Smith GH, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145-1155.
  64. Llibre JM, Pulido F, García F, et al. Genetic barrier to resistance for dolutegravir. AIDS Rev. 2015;17:56-64.
  65. Castagna A, Biswas P, Beretta A, et al. The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development. Drugs. 2005;65:879-904.
  66. Lalezari J, Dhody K, Kowalczyk U, et al. PRO140 single-agent maintenance therapy for hiv-1 infection: a 2-year update. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 437.
  67. ClinicalTrials.gov. Study of PRO 140 SC as single agent maintenance therapy in virally suppressed subjects with CCR5-tropic HIV-1 infection. Available at: https://clinicaltrials.gov/ct2/show/NCT02859961. Accessed April 17, 2017.
  68. ClinicalTrials.gov. A randomized, double-blind, placebo-controlled trial, followed by single-arm treatment of PRO 140 in combination w/ optimized background therapy in treatment-experienced HIV subjects (PRO 140). Available at: https://clinicaltrials.gov/ct2/show/NCT02483078. Accessed April 17, 2017.
  69. Tse WC, Link JO, Mulato A, et al. Discovery of novel potent HIV capsid inhibitors with long-acting potential. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 38.
  70. White KL, Margot N, Stray K, et al. GS-9131 is a novel NRTI with activity against NRTI-resistant HIV-1. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 436.
  71. Grobler J, McHale C, Freddo C, et al. MK-8591 concentrations at sites of HIV transmission and replication. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 435.
  72. Link JO, Kato D, Moore M, et al. Novel HIV PI with high resistance barrier and potential for unboosted QD oral dosing. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 433.
  73. Owen A, Rannard S, Jackson A, et al. Human confirmation of oral dose reduction potential of nanoparticle ARV formulations. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 39.
  74. Bekker L-G, Li SS, Tolley B, et al. HPTN 076: TMC278 LA safe, tolerable, and acceptable for HIV preexposure prophylaxis. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 421LB.
  75. Murphy R, Kravchenko AV, Orlova-Morozova E, et al. Elsulfavirine as compared to efavirenz in combination with TDF/FTC: 48-week study. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 452LB.
  76. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014;161:461-471.
  77. Althoff KN, Palella FJ, Gebo K, et al. Impact of smoking, hypertension & cholesterol on myocardial infarction in HIV+ adults. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 130.
  78. Shepherd L, Ryom L, Petoumenos K, et al. Cessation of cigarette smoking and the impact on cancer incidence in the D:A:D study. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 131.
  79. Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis. 2015;60:1278-1280.
  80. Lin HH, Lee SSJ, Wang NC, et al. Intramuscular ibalizumab: pharmacokinetics, safety, and efficacy vs IV administration. Program and abstracts of the 2017 Conference on Retroviruses and Opportunistic Infections; February 13-16, 2017; Seattle, Washington. Abstract 438.

Translated and published with permission. ©2020 Clinical Care Options, LLC

Disclaimer : Clinical Care Options is not responsible for the accuracy of the translation of this educational product,
including errors, omissions, or misinterpretations that may have occurred in the translation of this product from English to Japanese.

Practice Updates: HIV Managementは、ヴィーブヘルスケア株式会社からの教育助成金によりエイズ予防財団が選択したプログラムを提供しています。

ページトップへ